1 / 28

Individual Bioequivalence: Background and Concepts

Advisory Committee for Pharmaceutical Science. Individual Bioequivalence: Background and Concepts. Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical Science. November 28-29, 2001 Rockville, MD. Individual Bioequivalence Advantages.

alika-hays
Télécharger la présentation

Individual Bioequivalence: Background and Concepts

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Advisory Committee for Pharmaceutical Science Individual Bioequivalence:Background and Concepts Mei-Ling Chen, Ph.D.Associate Director Office of Pharmaceutical Science November 28-29, 2001 Rockville, MD

  2. Individual BioequivalenceAdvantages • Compares both population means and variances • Considers subject-by-formulation interaction • Establishes goalposts based on the reference variability for highly variable drug products • Creates incentive for both innovators and generic sponsors to manufacture less variable products • Encourages use of heterogeneous subjects that are more representative of the general population

  3. Individual Bioequivalence AssessmentDistance Concept • Individual Difference Ratio (IDR) Difference between T and R • IDR = ------------------------------------- Difference between R and R’ • Both T and R are administered to the same individual • Goal: IDR not substantially greater than 1

  4. Individual Bioequivalence (Average Difference)2 + Variance Terms • ------------------------------------------------------ BE LimitReference Variance (mT - mR)2 + sD2 + (sWT2 - sWR2) • ------------------------------------------- qIsWR2 • Variance Terms- Subject-by-formulation interaction (sD2) - Within-subject variances (sWT2, sWR2)

  5. Subject-by-Formulation Interaction • The S x F interaction is a measure of the extent to which the individual mean differences, mTj - mRj, between the T and R products are likely to differ. • sD2 = variance of (µTj - µRj) = (sBT - sBR)2 + 2 (1- ) sBTsBR • µTj, µRj : individual-specific means • sBT, sBR: between-subject standard deviations •  : correlation coefficient between µTj & µRj • sD2 : S x F interaction variance component

  6. Sources of S x F Interaction sD2 = var (µTj - µRj) = (sBT - sBR)2 + 2 (1- ) sBTsBR • Changes in between-subject variability for T and R formulation • Lack of congruence in individual means between T and R formulation

  7. Verapamil Immediate ReleaseAge-based SxF Interaction *SxF interaction occurred to Generic 1, but not Generic 2. Reference: Carter BL et al., Pharmacotherapy, 13, 1993

  8. Calcium Channel Blocker Gender-based S x F Interaction

  9. Interpretation of S x F Interaction • Approach 1Percentage of individuals whose average T/R ratios lie outside the range of 80-125% • Approach 2Presence of a subgroup(s) with a different average T/R ratio(s) from the remaining subjects of the population

  10. Proportion of Individuals With T/R Ratio Outside 80-125% (Assuming T/R mean ratio is 1.0) Approach 1 60 50 40 % 30 20 10 0 0.1 0.15 0.2 0.25 0.3 0.35 0.4 Sigma D Value

  11. Approach 2 S x F Interaction Due to Subgroups

  12. Individual Bioequivalence Criterion (mT - mR)2 + sD2 + (sWT2 - sWR2) ------------------------------------------- qIsWR2 • Reference Scaling • Away from the “one-size-fits-all” approach • Goalposts adjusted for highly variable drug products

  13. Mixed-Scaling Approach • Reference-Scaled (if sWR > sW0 )(mT - mR)2 + sD2 + (sWT2 - sWR2) ------------------------------------------- qIsWR2 • Constant-Scaled (if sWRsW0 ) (mT - mR)2 + sD2 + (sWT2 - sWR2) ------------------------------------------- qIsW02

  14. Constraint on Mean Difference (mT - mR)2 + sD2 + (sWT2 - sWR2) ------------------------------------------- qIsWR2 • Incentives for manufacturing less variable formulations • Mean-variance tradeoff • Possibility of a large mean difference • Guidance recommendation - Further constraint on the point estimate of geometric T/R mean ratio to be within 80-125%

  15. Advisory Committee for Pharmaceutical Science Replicate Design Studies:NDA’s and FDA Database Mei-Ling Chen, Ph.D.Associate Director Office of Pharmaceutical Science November 28-29, 2001 Rockville, MD

  16. Replicate Design Data NDAs and ANDAs

  17. Old Database

  18. New Data N= 17- 93

  19. Modified Release Products - NDAs

  20. Immediate Release Products - NDAs

  21. IR - Data Set #2 Subject #9

  22. FDA Contract Studies • Replicated-Crossover Design • Conducted at the University of Tennessee • Ranitidine • Metoprolol • Methylphenidate

  23. Interplay of Drugs and Excipients Drugs R Ranitidine Metoprolol (Low P) (High P) Excipient 1SorbitolLow permeability Osmotic pressureGI transit time Excipient 2 SucroseHigh permeability Bioavailability? SxF Interaction?

  24. Excipient EffectHypothesis • The bioavailability of a low permeability drug (e.g., ranitidine) is more likely to be affected by an excipient such as sorbitol that reduces the gastrointestinal transit time. • Subject-by-formulation interactions may occur when two syrup formulations contain different sweetening agents, e.g., sorbitol versus sucrose.

  25. Ranitidine Levels Failed ABE and IBE AUCinf, T/R = 0.56 Cmax, T/R = 0.49 (reference) (test)

  26. Metoprolol Levels AUCinf, T/R = 0.93 Cmax, T/R = 0.77 AUCinf Passed ABE & IBE Cmax Failed Both (reference) (test)

  27. Ranitidine in Sucrose vs. Sorbitol Solution Subject-by-Formulation Interaction Reduction of between-subject variability from sucrose to sorbitol resulted in an SxF interaction (sD = 0.15) sBR= 0.24 sBT= 0.13

  28. Methylphenidate

More Related